Detection of SARS-CoV-2 utilizing qRT-PCR in saliva obtained from asymptomatic or gentle COVID-19 sufferers, comparative evaluation with matched nasopharyngeal samples
Targets: The correct detection of extreme acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is important for the prognosis of coronavirus illness 2019 (COVID-19). We in contrast the quantitative RT-PCR outcomes between nasopharyngeal swabs and saliva specimens.
Strategies: A COVID-19 outbreak occurred on a cruise ship at Nagasaki port, Japan. We obtained 123 nasopharyngeal swabs and saliva every from asymptomatic or gentle sufferers within the late section of an infection.
Outcomes: The intervals from the prognosis to the sampling had been 25.5 days for nasopharyngeal swabs and 28.9 days for saliva. The optimistic fee was 19.5% (24/123) for nasopharyngeal swabs and 38.2% (47/123) for saliva (P = 0.48). The quantified viral copies (imply ± SEM copies/5 μl) had been 9.3±2.6 in nasopharyngeal swabs and 920±850 in saliva (P = 0.0006).
Conclusions: Some great benefits of saliva specimens embrace optimistic fee enchancment and correct viral load detection. Saliva could also be used as a dependable pattern for SARS-CoV-2 detection.

cDNA from Human Tumor Tissue: Colon |
|||
C1235090 | Biochain | 40 reactions | EUR 648 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Human Diabetic Tissue: Colon |
|||
C1236090Dia | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Mouse Normal Tissue: Colon |
|||
C1334090 | Biochain | 40 reactions | EUR 648 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Rat Normal Tissue: Colon |
|||
C1434090 | Biochain | 40 reactions | EUR 648 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Human Adult Normal Tissue: Colon |
|||
C1234090 | Biochain | 40 reactions | EUR 451.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Monkey (Rhesus) Normal Tissue: Colon |
|||
C1534090 | Biochain | 40 reactions | EUR 451.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Monkey (Cynomolgus) Normal Tissue: Colon |
|||
C1534090-Cy | Biochain | 40 reactions | EUR 451.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Human Adult Normal Tissue: Colon Ascending |
|||
C1234091 | Biochain | 40 reactions | EUR 451.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Human Adult Normal Tissue: Colon Descending |
|||
C1234092 | Biochain | 40 reactions | EUR 451.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Human Adult Normal Tissue: Colon Sigmoid |
|||
C1234095 | Biochain | 40 reactions | EUR 451.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Human Adult Normal Tissue: Colon Transverse |
|||
C1234096 | Biochain | 40 reactions | EUR 451.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Monkey (Rhesus) Normal Tissue: Colon Ascending |
|||
C1534091 | Biochain | 40 reactions | EUR 648 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Monkey (Rhesus) Normal Tissue: Colon descending |
|||
C1534092 | Biochain | 40 reactions | EUR 648 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Monkey (Rhesus) Normal Tissue: Colon Sigmoid |
|||
C1534095 | Biochain | 40 reactions | EUR 648 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Monkey (Rhesus) Normal Tissue: Colon Transverse |
|||
C1534096 | Biochain | 40 reactions | EUR 648 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
Matching Pair - cDNA from Human Primary Tumor and Normal Tissue: Colon |
|||
C8235090-PP | Biochain | 10 reactions x2 | EUR 598.8 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
Colon |
|||
TMA2081 | TissueArray | each | EUR 546 |
Description: Colon, prostate and breast tissue array, 156 cases/208 cores |
Matching Pair - cDNA from Human Primary and Matched Metastatic Tumor Tissue: Colon |
|||
C8235090-PM | Biochain | 10 reactions x2 | EUR 1180.8 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
Colon cancer with colon tissue array |
|||
CO1021a | TissueArray | each | EUR 306 |
Description: Colon cancer with colon tissue array, including pathology grade, with MMR (MLH1/PMS2/MSH2/MSH6) IHC results,TNM and clinical stage, containing 86 cases of adenocarcinoma, 4 papillary adenocarcinoma, 7 mucinous adenocarcinoma, 2 adenoma, 1 congenital megacolon, 2 colon tissue, 102 cases/102 cores replacing CO1021 |
Colon cancer with colon tissue array |
|||
CO1921 | TissueArray | each | EUR 546 |
Description: Colon cancer with colon tissue array, including pathology grade, TNM and clinical stage, 192 cases/192 cores |
Colon cancer with colon tissue array |
|||
CO2161b | TissueArray | each | EUR 474 |
Description: Colon cancer with colon tissue array, including pathology grade, TNM and clinical stage, 216 cases/216 cores, replacing CO2161a |
Colon adenocarcinoma with colon tissue array |
|||
CO483b | TissueArray | each | EUR 198 |
Description: Colon adenocarcinoma with colon tissue array, including pathology, TNM and clinical stage, 48 cases/48 cores, replacing CO483a |
Colon cancer with colon tissue array |
|||
CO721 | TissueArray | each | EUR 270 |
Description: Colon cancer with colon tissue array, including pathology grade, TNM and clinical stage, 24 cases/72 cores |
Colon cancer with colon tissue array |
|||
CO805 | TissueArray | each | EUR 258 |
Description: Colon cancer with colon tissue array, including pathology grade, TNM and clinical stage, 40 cases/80 cores |
Genorise® Bovine IL-1b cDNA Clone, 10 ug |
|||
GR152001 | Genorise Scientific | 10 µg | EUR 183.6 |
Colon Lysate |
|||
21-179 | ProSci | 0.1 mg | EUR 342.6 |
Description: Monkey (Cynomolgus) colon tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The monkey (Cynomolgus) colon tissue total protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the colon tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The colon tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot. |
Colon Lysate |
|||
21-288 | ProSci | 0.1 mg | EUR 342.6 |
Description: Monkey (Rhesus) colon tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The monkey (Rhesus) colon tissue total protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the colon tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The colon tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot. |
Colon Lysate |
|||
1472 | ProSci | 0.1 mg | EUR 229.2 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Colon carcinoma |
|||
CO1005a | TissueArray | each | EUR 306 |
Description: Colon carcinoma, metastatic carcinoma and colon adenoma tissue array with colon tissue as control, including pathology grade, TNM and clinical stage (reference AJCC 8th version), 98 cases/100 cores, replacing CO1005 |
Colon tissue array with colon cancer tissue |
|||
BN05014a | TissueArray | each | EUR 222 |
Description: Colon tissue array with colon cancer tissue, including pathology grade, TNM and clinical stage, 24 cases/72 cores, replacing BN05014 |
Colon adenocarcinoma tissue array with colon tissue |
|||
CO1201 | TissueArray | each | EUR 348 |
Description: Colon adenocarcinoma tissue array with colon tissue, with pathology grade, TNM/Stage, 120 cases/120 cores (core size 1.0mm), replacing BC051110c |
Colon cancer with matched colon tissue array |
|||
CO1801a | TissueArray | each | EUR 474 |
Description: Colon cancer with matched colon tissue array, including pathology grade,with MMR (MLH1/PMS2/MSH2/MSH6) IHC results, TNM and clinical stage, containing 90 cases of adenocarcinoma, and 90 cancer adjacent or adjacent normal colon tissue, 90 cases/180 cores, replacing CO1801 |
Colon cancer with matched colon tissue array |
|||
CO602a | TissueArray | each | EUR 222 |
Description: Colon cancer with matched colon tissue array, including pathology grade, TNM and clinical stage, 30 cases/60 cores, replacing CO602 |
Colon cancer with matched colon tissue array |
|||
CO703 | TissueArray | each | EUR 198 |
Description: Colon cancer with matched colon tissue array, including pathology grade, TNM and clinical stage, 35 cases/70 cores,replaced by CO703a |
Colon cancer with adjacent normal colon tissue array |
|||
CO2001a | TissueArray | each | EUR 474 |
Description: Colon cancer with adjacent normal colon tissue array, including TNM and pathology grade with MMR (MLH1/PMS2/MSH2/MSH6) IHC results, containing 140 cases of adenocarcinoma, 52 cases of mucinous adenocarcinoma and 8 adjacent normal colon tissue, 200 cases/ 200 cores, replacing CO2001 |
Colon cancer with matched adjacent normal colon tissue |
|||
CO321a | TissueArray | each | EUR 168 |
Description: Colon cancer with matched adjacent normal colon tissue, including pathology grade, TNM and clinical stage, 16 cases/32 cores, replacing CO321 |
Colon adenocarcinoma with matched adjacent colon tissue array |
|||
CO487 | TissueArray | each | EUR 168 |
Description: Colon adenocarcinoma with matched adjacent colon tissue array, including TNM and pathology grade, 16 cases/48 cores |
High-density colon cancer with colon tissue array |
|||
CO6161 | TissueArray | each | EUR 954 |
Description: High-density colon cancer with colon tissue array, including pathology grade, TNM and clinical stage, 322 cases/616 cores |
Colon cancer with adjacent normal colon tissue array |
|||
CO806 | TissueArray | each | EUR 270 |
Description: Colon cancer with adjacent normal colon tissue array, replacing BN05012, 80 cases/80 cores |
Colon disease spectrum (colon cancer progression) tissue array |
|||
CO808 | TissueArray | each | EUR 306 |
Description: Colon disease spectrum (colon cancer progression) tissue array, including pathology grade, TNM and clinical stage, 76 cases/80 cores |
Colon cancer tissue array with normal colon tissue |
|||
T054c | TissueArray | each | EUR 48 |
Description: Colon cancer tissue array with normal colon tissue, including TNM, clinical stage and pathology grade, 12 cases/ 24 cores, replaced by T054d |
cDNA Synthesis SuperMix |
|||
20-abx09801420ulSystems | Abbexa |
|
|
Novo? cDNA Kit |
|||
M1165-100 | Biovision | each | EUR 424.8 |
Novo? cDNA Kit |
|||
M1165-25 | Biovision | each | EUR 320.4 |
Evo? cDNA Supermix |
|||
M1168-100 | Biovision | each | EUR 457.2 |
Evo? cDNA Supermix |
|||
M1168-25 | Biovision | each | EUR 320.4 |
Novo? cDNA Supermix |
|||
M1169-100 | Biovision | each | EUR 529.2 |
Novo? cDNA Supermix |
|||
M1169-25 | Biovision | each | EUR 346.8 |
Colon Lupus Lysate |
|||
XBL-10335 | ProSci | 0.1 mg | EUR 796.2 |
Description: Human colon tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human colon tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the colon tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The colon tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot. |
Fetal Colon Lysate |
|||
XBL-10403 | ProSci | 0.1 mg | EUR 342.6 |
Description: Fetal human colon tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The fetal human colon tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the colon tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The colon tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot. |
Colon Cytoplasmic Lysate |
|||
XBL-10504 | ProSci | 0.1 mg | EUR 273.3 |
Description: Human colon tissue cytoplasmic protein lysate was prepared by isolating the cytoplasmic protein from whole tissue homogenates using a proprietary technique. The human colon tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The cytoplasmic protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, glycerol, and a cocktail of protease inhibitors. For quality control purposes, the isolated colon tissue cytoplasmic protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated colon tissue cytoplasmic protein is then Western analyzed by GAPDH antibody, and the expression level is consistent with each lot. |
Colon Membrane Lysate |
|||
XBL-10505 | ProSci | 0.1 mg | EUR 619.8 |
Description: Human colon tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human colon tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated colon tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated colon tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal. |
Progressive colon adenocarcinoma |
|||
CO1506 | TissueArray | each | EUR 258 |
Description: Progressive colon adenocarcinoma, matched cancer adjacent with normal adjacent tissue array, including pathology grade, TNM /Stage ( AJCC 8th version) and MMR (MLH1/PMS2/MSH2/MSH6) IHC results, 50 cases/150cores (core size 1.0mm),Recent Year Collection |
Colon adenocarcinoma TMA |
|||
CO571 | TissueArray | each | EUR 270 |
Description: Colon adenocarcinoma TMA, 5 samples have matched cancer adjacent tissue samples, including pathology grade, TNM and clinical stage (reference AJCC 8th version) with MMR (MLH1/PMS2/MSH2/MSH6) IHC results, 52 cases/ 57 cores (core size 1.5mm) Recent Year Collection |
Colon cancer tissue array with normal colon tissue and adjacent colon tissue as control |
|||
CO20811a | TissueArray | each | EUR 546 |
Description: Colon cancer tissue array with normal colon tissue and adjacent colon tissue as control, including TNM and pathology grade with MMR (MLH1/PMS2/MSH2/MSH6) IHC results,208 cases/ 208 cores, replacing CO20811 |
cDNA from Plant Normal Tissue: cDNA from Plant: Arabidopsis |
|||
C1634310 | Biochain | 40 reactions | EUR 745.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Plant Normal Tissue: cDNA from Plant: Corn |
|||
C1634330 | Biochain | 40 reactions | EUR 745.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Plant Normal Tissue: cDNA from Plant: Orange |
|||
C1634340 | Biochain | 40 reactions | EUR 745.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Plant Normal Tissue: cDNA from Plant: Potato |
|||
C1634350 | Biochain | 40 reactions | EUR 745.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Plant Normal Tissue: cDNA from Plant: Rice |
|||
C1634360 | Biochain | 40 reactions | EUR 745.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Plant Normal Tissue: cDNA from Plant: Wheat |
|||
C1634390 | Biochain | 40 reactions | EUR 745.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
High-density colon cancer and normal colon tissue array |
|||
CO208a | TissueArray | each | EUR 546 |
Description: High-density colon cancer and normal colon tissue array, 64 cases/192 cores, including TNM and pathology grade, 64 cases/192 cores (core size 1.0mm), replaced by CO208b |
Colon cancer tissue array with adjacent normal colon tissue |
|||
CO241a | TissueArray | each | EUR 66 |
Description: Colon cancer tissue array with adjacent normal colon tissue, including TNM, clinical stage and pathology grade, 6 cases/24 cores |
Multiple types of colon disease with colon tissue array |
|||
CO245a | TissueArray | each | EUR 66 |
Description: Multiple types of colon disease with colon tissue array, including crohn‘s disease, chronic inflammation of the colonic mucosa, ulcerative colitis, adenocarcinoma, 12 cases/24 cores (core size 1.5mm), replacing CO245 |
Progression of colon disease (IBD) with colon tissue array |
|||
CO246 | TissueArray | each | EUR 66 |
Description: Progression of colon disease (IBD) with colon tissue array, 5 cases of crohn's disease, 2 ulcerative colitis, 5 normal colon tissue, 12 cases/24 cores |
Colon cancer with colon tissue array (2010 WHO classification) |
|||
CO701a | TissueArray | each | EUR 306 |
Description: Colon cancer with colon tissue array (2010 WHO classification), including pathology grade, TNM and clinical satge (AJCC 7th edition), 70 cases/70 cores, replacing CO701 |
Different stages of colon cancer and colon tissue array |
|||
CO807 | TissueArray | each | EUR 306 |
Description: Different stages of colon cancer and colon tissue array, including pathology grade, TNM and clinical satge, 80 cases/80 cores |
cDNA from Plant Normal Tissue: cDNA from Plant: Soy bean |
|||
C1634370 | Biochain | 40 reactions | EUR 745.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
First-Strand cDNA Synthesis SuperMix (cDNA up to 12 kb) |
|||
20-abx09801620ulSystems | Abbexa |
|
|
First-Strand cDNA Synthesis SuperMix (cDNA up to 15 kb) |
|||
20-abx09802120ulSystems | Abbexa |
|
|
Colon cancer tissue with matched adjacent normal colon tissue array |
|||
BC05118d | TissueArray | each | EUR 306 |
Description: Colon cancer tissue with matched adjacent normal colon tissue array, including TNM, clinical stage and pathology grade, 50 cases/100 cores |
Normal colon tissue array with colon cancer tissue as control |
|||
CO727 | TissueArray | each | EUR 270 |
Description: Normal colon tissue array with colon cancer tissue as control, including TNM, clinical stage and pathology grade, 24 cases/ 72 cores |
Colon cancer tissue array with matched adjacent normal colon tissue |
|||
CO801a | TissueArray | each | EUR 270 |
Description: Colon cancer tissue array with matched adjacent normal colon tissue, including TNM, clinical stage and pathology grade, 40 cases/ 80 cores, replced by CO801b |
cDNA from Arteriosclerosis: Aorta |
|||
C1236012Hd-4 | Biochain | 40 reactions | EUR 973.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from hypertension: Artery |
|||
C1236013Hd-2 | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Arteriosclerosis: Artery |
|||
C1236013Hd-4 | Biochain | 40 reactions | EUR 973.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from hypertension: Vein |
|||
C1236020Hd-2 | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from hypertension: Heart |
|||
C1236122Hd-2 | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Lupus: Heart |
|||
C1236122Lup | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from hypertension: Kidney |
|||
C1236142Hd-2 | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Lupus: Kidney |
|||
C1236142Lup | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Lupus: Liver |
|||
C1236149Lup | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Asthma: Lung |
|||
C1236152Ld-1 | Biochain | 40 reactions | EUR 973.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Bronchitis: Lung |
|||
C1236152Ld-2 | Biochain | 40 reactions | EUR 973.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Emphysema: Lung |
|||
C1236152Ld-3 | Biochain | 40 reactions | EUR 973.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Pneumonia: Lung |
|||
C1236152Ld-4 | Biochain | 40 reactions | EUR 973.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Lupus: Lung |
|||
C1236152Lup | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Lupus: Pancreas |
|||
C1236188Lup | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Lupus: Spleen |
|||
C1236246Lup | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Lupus: stomach |
|||
C1236248Lup | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
Human eNOS cDNA probe |
|||
eNOS51-D-2 | Alpha Diagnostics | 2 ug | EUR 534 |
Tetro cDNA Synthesis Kit |
|||
BIO-65042 | Bioline | 30 Reactions | Ask for price |
Tetro cDNA Synthesis Kit |
|||
BIO-65043 | Bioline | 100 Reactions | Ask for price |
SensiFAST cDNA Synthesis Kit |
|||
BIO-65053 | Bioline | 50 Reactions | Ask for price |
SensiFAST cDNA Synthesis Kit |
|||
BIO-65053/S | Bioline | Sample | Ask for price |
SensiFAST cDNA Synthesis Kit |
|||
BIO-65054 | Bioline | 250 Reactions | Ask for price |
cDNA Probe Diluent Solution |
|||
AR0063 | BosterBio | 5mL | EUR 127.2 |
OneScriptPlus cDNA Synthesis Kit |
|||
G235 | ABM | 25 x 20 ul reactions | EUR 116.4 |
OneScriptPlus cDNA Synthesis Kit |
|||
G236 | ABM | 100 x 20 ul reactions | EUR 202.8 |
OneScriptPlus cDNA Synthesis SuperMix |
|||
G453 | ABM | 25 x 20 ul reactions | EUR 116.4 |
OneScriptPlus cDNA Synthesis SuperMix |
|||
G454 | ABM | 100 x 20 ul reactions | EUR 202.8 |
circRNA cDNA Synthesis Kit |
|||
G627 | ABM | 25 rxn (20 ul/rxn) | EUR 370.8 |
Plant Tissue cDNA: Arabidopsis |
|||
PC34-310 | Alpha Diagnostics | 10 rxn | EUR 498 |
EVery cDNA Synthesis Kit |
|||
EVery200B-1 | SBI | 20 preps | EUR 307 |
Evo™ cDNA Kit |
|||
M1164-100 | Biovision | each | Ask for price |
Evo™ cDNA Kit |
|||
M1164-25 | Biovision | each | Ask for price |
Novo? Transcriptome cDNA Kit |
|||
M1167-100 | Biovision | each | EUR 1142.4 |
Novo? Transcriptome cDNA Kit |
|||
M1167-25 | Biovision | each | EUR 529.2 |
Colon Tissue Lysate (Normal) |
|||
1715-01 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-02 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-03 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-04 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-05 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-06 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-07 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-08 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-10 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-11 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-12 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-13 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-14 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-15 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-16 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-17 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-19 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-20 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-21 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-22 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Tumor) |
|||
1716-01 | ProSci | 0.1 mg | EUR 336.3 |
Description: Colon tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Tumor) |
|||
1716-02 | ProSci | 0.1 mg | EUR 336.3 |
Description: Colon tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Tumor) |
|||
1716-03 | ProSci | 0.1 mg | EUR 336.3 |
Description: Colon tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Tumor) |
|||
1716-04 | ProSci | 0.1 mg | EUR 336.3 |
Description: Colon tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Human Colon Tumor lystae |
|||
HTL-1327 | Alpha Diagnostics | 100ug | EUR 343.2 |
Anti-Colon Carcinoma antibody |
|||
STJ16100736 | St John's Laboratory | 1 mL | EUR 422.4 |
Anti-Colon Carcinoma antibody |
|||
STJ16100744 | St John's Laboratory | 1 mL | EUR 422.4 |
Immortalized Human Colon Cells |
|||
T0570 | ABM | 1x106 cells / 1.0 ml | Ask for price |
Trichrome - Colon (Control Slides) |
|||
TCS0021-100 | ScyTek Laboratories | 100 Slides | EUR 847.2 |
Trichrome - Colon (Control Slides) |
|||
TCS0021-25 | ScyTek Laboratories | 25 Slides | EUR 278.4 |
Trichrome - Colon (Control Slides) |
|||
TCS0021-5 | ScyTek Laboratories | 5 Slides | EUR 117.6 |
Colon Diabetic Disease Lysate |
|||
XBL-10333 | ProSci | 0.1 mg | EUR 796.2 |
Description: Human colon tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human colon tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the colon tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The colon tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot. |
Colon Liver Cirrhosis Lysate |
|||
XBL-10334 | ProSci | 0.1 mg | EUR 796.2 |
Description: Human colon tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human colon tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the colon tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The colon tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot. |
Colon Membrane Tumor Lysate |
|||
XBL-10520 | ProSci | 0.1 mg | EUR 752.1 |
Description: Human colon tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human colon tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated colon tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated colon tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal. |
Ascending Colon Membrane Lysate |
|||
XBL-10523 | ProSci | 0.1 mg | EUR 619.8 |
Description: Human colon ascending tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human colon ascending tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated colon ascending tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated colon ascending tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal. |
Descending Colon Membrane Lysate |
|||
XBL-10526 | ProSci | 0.1 mg | EUR 619.8 |
Description: Human colon descending tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human colon descending tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated colon descending tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated colon descending tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal. |
Colon carcinoma tissue array |
|||
CO1006 | TissueArray | each | EUR 306 |
Description: Colon carcinoma tissue array, including TNM, clinical stage and pathology grade, 50cases/100 cores |
Colon adenocarcinoma tissue array |
|||
CO1251 | TissueArray | each | EUR 270 |
Description: Colon adenocarcinoma tissue array, including ulcer, uplift and infiltrating type adenocarcinoma, with pathology grade, TNM/Stage ( AJCC 8th edition) and MMR (MLH1/PMS2/MSH2/MSH6) IHC results, 125 cases/125cores (core size 1.5mm), Recent Year Collection |
Colon adenocarcinoma tissue array |
|||
CO1501 | TissueArray | each | EUR 258 |
Description: Colon adenocarcinoma tissue array, including TNM and pathology grade, 75 cases/150 cores |
Colon cancer tissue array |
|||
CO1502 | TissueArray | each | EUR 258 |
Description: Colon cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases/150 cores |
Colon cancer tissue array |
|||
CO1503 | TissueArray | each | EUR 258 |
Description: Colon cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases/150 cores |
Colon cancer tissue array |
|||
CO244 | TissueArray | each | EUR 270 |
Description: Colon cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases/48 cores |
Colon cancer tissue array |
|||
CO485 | TissueArray | each | EUR 270 |
Description: Colon cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases/48 cores |
Colon cancer tissue array |
|||
CO486a | TissueArray | each | EUR 414 |
Description: Colon cancer tissue array, including pathology grade, TNM and clinical stage, 2 serial sections, 48 cases/96 cores, replacing CO486 |
Colon cancer tissue array |
|||
CO641 | TissueArray | each | EUR 258 |
Description: Colon cancer tissue array, including TNM, stage and pathology grade, 64 cases/ 64 cores |
Colon cancer tissue array |
|||
CO804b | TissueArray | each | EUR 270 |
Description: Colon cancer tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores, replcing CO804a |
Colon disease tissue array |
|||
CO809b | TissueArray | each | EUR 306 |
Description: Colon disease tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores, replacing CO809a |
Colon cancer tissue array |
|||
CO901a | TissueArray | each | EUR 306 |
Description: Colon cancer tissue array, with adjacent normal colon tissue, including TNM, clinical stage and pathology grade, 50 cases/90 cores, replacing CO901 |
Colon cancer tissue array |
|||
CO961 | TissueArray | each | EUR 258 |
Description: Colon cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases/96 cores |
Colon cancer tissue array |
|||
CO962 | TissueArray | each | EUR 258 |
Description: Colon cancer tissue array, including pathology grade, TNM/Stage, 48 cases/96 cores |
Colon cancer tissue array |
|||
CRM1503 | TissueArray | each | EUR 420 |
Description: Colon cancer tissue array, 150 cases/150 cores |
Colon cancer tissue array |
|||
CRM1504 | TissueArray | each | EUR 420 |
Description: Colon cancer tissue array, 150 cases/150 cores |
Colon cancer tissue array |
|||
CRM1506 | TissueArray | each | EUR 420 |
Description: Colon cancer tissue array, 150 cases/150 cores |
Colon cancer tissue array |
|||
CRM1507 | TissueArray | each | EUR 420 |
Description: Colon cancer tissue array, 150 cases/150 cores |
Colon carcinoma tissue array with adjacent normal colon tissue as control |
|||
CO242b | TissueArray | each | EUR 66 |
Description: Colon carcinoma tissue array with adjacent normal colon tissue as control, including TNM, clinical stage and pathology grade, 12 cases/24 cores, replacing CO242a |
Colon cancer with matched colon tissue array (most in grade II) |
|||
CO703a | TissueArray | each | EUR 198 |
Description: Colon cancer with matched colon tissue array (most in grade II), including pathology grade, TNM and clinical stage, 35 cases/70 cores |
Colon carcinoma tissue array with matched adjacent normal colon tissue as control |
|||
CO243a | TissueArray | each | EUR 66 |
Description: Colon carcinoma tissue array with matched adjacent normal colon tissue as control, including TNM, clinical stage and pathology grade, 12 cases/24 cores, replaced by CO243b |
Colon carcinoma tissue array with matched adjacent normal colon tissue as control |
|||
CO243b | TissueArray | each | EUR 66 |
Description: Colon carcinoma tissue array with matched adjacent normal colon tissue as control, including TNM, clinical stage and pathology grade, 12 cases/24 cores, replacing CO243a |
cDNA from Alzheimer's Disease: Brain |
|||
C1236035Alz | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Liver Cirrhosis: Brain |
|||
C1236035Lcs | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Parkinson's Disease: Brain |
|||
C1236035Par | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Dementia: Brain: Hippocampus |
|||
C1236052Dem | Biochain | 40 reactions | EUR 961.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Depression: Brain: Hippocampus |
|||
C1236052Dep | Biochain | 40 reactions | EUR 961.2 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Liver Cirrhosis: Esophagus |
|||
C1236106Lcs | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Liver Cirrhosis: Heart |
|||
C1236122Lcs | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from hypertension: Interventricular Septum |
|||
C1236130Hd-2 | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Liver Cirrhosis: Kidney |
|||
C1236142Lcs | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
cDNA from Liver Cirrhosis: Liver |
|||
C1236149Lcs | Biochain | 40 reactions | EUR 801.6 |
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
Comparative Analysis of Two Automated Multiplex RT-PCR Assessments for Fast Detection of Influenza and Respiratory Syncytial Viruses
Background: Fast and correct prognosis of influenza virus (Flu) and respiratory syncytial virus (RSV) is vital for managing each the affected person and laboratory. We in contrast the cobas Influenza A/B & RSV assay (cobas Liat) with the Simplexa Flu A/B & RSV assay (Simplexa) to guage which check methodology is extra advantageous contemplating the sources of the laboratory and outcomes of check efficiency.
Strategies: A complete of 236 respiratory specimens from sufferers referred for respiratory virus testing had been retrospectively evaluated; 53 specimens examined optimistic for every of Flu A, Flu B, and RSV, and 77 specimens examined unfavorable based mostly on the outcomes of the reference methodology, i.e., the Seegene Allplex Respiratory Panel half/3 (Seegene, Seoul, Korea). The turnaround time (TAT) was 20 minutes per specimen for cobas Liat and 78 minutes per eight speci-mens for Simplexa. The overall hands-on time was round one minute per specimen for each assessments. The specimen quantity required for testing was 200 µL for cobas Liat and 50 µL for Simplexa. Seegene Allplex Respiratory Panel half/Three was used because the reference methodology.
Outcomes: The variety of invalid outcomes was 1 (0.4%) for cobas Liat and 10 (4.2%) for Simplexa (p < 0.05). All outcomes had been according to these of the reference methodology in cobas Liat. The sensitivity and specificity for Flu A, Flu B, and RSVA had been 100% with Simplexa. Nevertheless, the sensitivity for RSVB was 80.0% with Simplexa, which was a statistically vital distinction with the discovering for cobas Liat (p < 0.05). Comparability of the cycle threshold (Ct) values of RSV for Simplexa with the reference methodology confirmed correlation as steady variables (p < 0.001) with a better propensity for acquiring Ct values with Simplexa, the exception being the six false unfavorable outcomes; their Ct values had been greater than 30 within the reference methodology.
Conclusions: Cobas Liat confirmed correct efficiency with a fast TAT and an excellent workflow effectivity. Cobas Liat is extra environment friendly than Simplexa as a point-of-care check for the detection of RSV.
Disagreement between PCR and serological prognosis of Trypanosoma cruzi an infection in blood donors from a Colombian endemic area
Introduction: Chagas’ illness is the main reason behind infectious myocarditis worldwide. This an infection brought on by Trypanosoma cruzi is often life-long and asymptomatic; nonetheless, the third a part of contaminated folks can develop extreme and even deadly cardiomyopathy. Because the parasitemia within the persistent section is each low-grade and intermittent, T. cruzi an infection is principally detected by serology, though this methodology has sensitivity and specificity limitations.
Goal: To find out the extent of settlement between serologic and molecular assessments in 658 voluntary blood donors from six provinces within the Colombian division of Santander.
Supplies and strategies: We evaluated an array of diagnostic applied sciences by cross-section sampling performing a serological double diagnostic check for T. cruzi antibody detection (Chagas III ELISA™, BiosChile Group, and ARCHITECT Chagas CMIA™, Abbott), and DNA detection by polymerase chain response (PCR). We collected the demographic, medical, and epidemiological data of contributors. The pattern measurement was calculated utilizing Epidat™ and the statistical evaluation was finished with Stata 12.1™.
Outcomes: PCR was six occasions extra delicate in detecting T. cruzi an infection than ELISA/CMIA with prevalence values of 1.8% (12/658) and 0.3% (2/658), respectively, and kappa=0.28 (95%CI: -0.03 – 0.59). In distinction, serology confirmed a sensitivity of 16.7% (95%CI: 2.09 – 48.4) and a specificity of 100% (95%CI: 99.4 – 100). All seropositive samples had been discovered to be optimistic by PCR.
Conclusions: The implementation of PCR as a complementary methodology for screening donors might scale back the likelihood of false unfavorable and the resultant danger of transfusional-transmission of Chagas’ illness, particularly in endemic areas.
Simultaneous screening of the FRAXA and FRAXE loci for fast detection of FMR1 CGG and/or AFF2 CCG repeat expansions by triplet-primed PCR
Reasonable to hyper growth of trinucleotide repeats on the FRAXA and FRAXE fragile websites, with or with out concomitant hypermethylation are related to mental incapacity and different situations. Not like molecular prognosis of FMR1 CGG repeat expansions in FRAXA, present detection of AFF2 CCG repeat expansions in FRAXE depends on low-throughput and inefficient strategies combining Southern blot and PCR. A novel triplet-primed PCR assay was developed to concurrently display for trinucleotide repeat expansions on the FRAXA and FRAXE fragile websites, and validated utilizing archived medical samples of identified FMR1 and AFF2 genotypes.
Sequencing of inhabitants samples and FRAXE-affected samples was carried out to guage variation of the AFF2 CCG repeat construction. The duplex assay precisely recognized expansions on the FMR1 and AFF2 trinucleotide repeat loci. Sanger sequencing of the AFF2 CCG repeat revealed that the SNP variant rs868914124(C), which successfully provides two CCG repeats at the 5′ finish, is enriched within the Malay inhabitants and with brief repeats (<11 CCGs), and was current in all six expanded AFF2 alleles of this research. All expanded AFF2 alleles contained a number of non-CCG interruptions in the direction of the 5′ finish of the repeat. We’ve developed a delicate, sturdy and fast assay to concurrently detect growth mutations on the FMR1 and AFF2 trinucleotide repeat loci, simplifying the screening of FRAXA and FRAXE related issues.